With 2018 drawing to a close, we took a look back at the Cancer Currents posts published over the last 12 months.
As our coverage shows, 2018 has been a year of important advances in cancer research. Some of our most-read posts were those about new treatment options for a variety of cancers, including childhood cancers. But posts about the side effects of cancer treatment and the cost of cancer drugs also received great interest.
In case you missed them when they were first posted or you want to read them again or share them with a friend, here are our top 10 most-read posts of 2018.
Thank you again for your interest and support. We hope you'll continue to read the blog and encourage others to subscribe.
For people with early-stage pancreatic cancer, results from two clinical trials suggest that altering the type and timing of chemotherapy improves survival. The findings will likely change the standard of care.
The opioid epidemic is having a significant impact on cancer patients, says Dr. Judith Paice of Northwestern University. She explains how oncologists can address concerns about opioid misuse when managing cancer pain.
Researchers are hopeful that, for the deadly brain cancer glioblastoma, immunotherapy might succeed where other therapies have not. Different immunotherapy approaches are being tested in clinical trials.
Cancer treatments known as oncolytic viruses are being tested in clinical trials, and one, T-VEC or Imlygic®, has been approved by the FDA. Research now suggests that these treatments work not only by infecting and killing tumor cells, but that they may also be a form of cancer immunotherapy.
A new study shows that 90% of postmenopausal women diagnosed with endometrial cancer reported vaginal bleeding before their diagnosis. Approximately 9% of women who saw a doctor for bleeding, the study showed, later received an endometrial cancer diagnosis.
The President's Cancer Panel has released its report, Promoting Value, Affordability, and Innovation in Cancer Drug Treatment. The report recommends six actions to maximize the value and affordability of cancer drug treatment.
The investigational drug selumetinib shrank tumors in some children with a genetic syndrome called neurofibromatosis type 1 (NF1). The drug also improved symptoms related to tumors known as neurofibromas, which can cause pain, difficulty breathing or walking, and disfigurement.
Three new studies have identified intestinal bacteria that appear to influence the response to checkpoint inhibitors. Researchers think their findings could be used to improve patients' responses to these immunotherapy drugs.
The combination of the immune checkpoint inhibitors ipilimumab (Yervoy) and nivolumab (Opdivo) has been approved by FDA for the treatment of patients with metastatic colorectal cancer whose tumor cells have DNA repair defects.
